Axxcess Wealth Management LLC Sells 1,166 Shares of Edwards Lifesciences Co. (NYSE:EW)

Axxcess Wealth Management LLC reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 9.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,645 shares of the medical research company’s stock after selling 1,166 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Edwards Lifesciences were worth $788,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in EW. Harbor Capital Advisors Inc. raised its position in shares of Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after acquiring an additional 273 shares in the last quarter. Nordea Investment Management AB increased its holdings in Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after purchasing an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its stake in Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after buying an additional 300,000 shares during the period. Sivik Global Healthcare LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $3,702,000. Finally, Avanza Fonder AB acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $4,845,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $70.91 on Friday. The business’s fifty day simple moving average is $71.48 and its 200 day simple moving average is $70.35. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The firm has a market capitalization of $41.69 billion, a P/E ratio of 10.17, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity

In other news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,303 shares of company stock valued at $3,715,776 in the last three months. Company insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on EW shares. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Piper Sandler upped their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Truist Financial reiterated a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Citigroup boosted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.